approval
saveTAFINLAR (DABRAFENIB MESYLATE) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 192d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 26, 2026 · 192d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 545d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalApr 7, 2025 · 545d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 564d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 19, 2025 · 564d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 576d ago
- approvalTAFINLAR (DABRAFENIB MESYLATE) — FDA approvalMar 7, 2025 · 576d ago
same company · ±60 days · 6
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalMay 26, 2023
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalMay 11, 2023
- approvalasciminib hydrochloride: SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalJun 26, 2023
- approvalinclisiran: LEQVIO (INCLISIRAN SODIUM) — FDA approvalJul 7, 2023
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalJul 24, 2023
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalJul 24, 2023
comments(0)
5-min edit window · permanent after that